Immobilized BCMA/TNFRSF17 His Tag Protein, Human(UA010083) can bind Belantamab. The EC50 for this effect is 2.062 ng/mL.
Anti-TNFRSF17/CD269/BCMA/TNFRSF13A Monoclonal Antibody (Belantamab)
Anti-TNFRSF17/CD269/BCMA/TNFRSF13A Monoclonal Antibody (Belantamab)
Price:
Regular price
$433 USD
Regular price
Sale price
$433 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Clone Number | S-SC040 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | Blocking of TNFRSF17/CD269/BCMA/TNFRSF13A signaling Functional assays |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 5 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
Belantamab is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), specifically designed for the treatment of relapsed or refractory multiple myeloma. The drug is composed of a humanized monoclonal antibody that specifically binds to BCMA, a stable linker, and the potent cytotoxic agent monomethyl auristatin F (MMAF), which precisely delivers the toxin into myeloma cells. It kills cancer cells by disrupting microtubule structure and inducing immune responses.
Picture
Picture
ELISA
